Immunome IMNM
NASDAQ IMNM
$21.11 +0.22 (+1.05%)
As of: Oct 2, 2026 · 9:40 AM EDT

Immunome (IMNM) Non-Current Deffered Revenue (2023 - 2024)

Updated

Immunome (IMNM) posted Non-Current Deffered Revenue of $2.21 million for Q1 2024, down 76.6% from $9.42 million a year earlier and down 59.8% from the prior quarter.

Analysis

Immunome (IMNM) Non-Current Deffered Revenue (2023 - 2024) Analysis & Trends

At the end of FY2023, Immunome's Non-Current Deffered Revenue came in at $5.49 million.

  • According to Business Quant data, Non-Current Deffered Revenue for the three prior quarters was $5.49 million (Q4 2023), $2.85 million (Q3 2023) and $5.71 million (Q2 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Immunome 2.44 Bn 410.39 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 2.21 Mn
Dec 31, 2023 5.49 Mn
Sep 30, 2023 2.85 Mn
Jun 30, 2023 5.71 Mn
Mar 31, 2023 9.42 Mn
API Access

Immunome Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=IMNM&period=max&api_key=YOUR_API_KEY